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Abstract
BACKGROUND—There are currently no assessments of the impact of surgical complications on 
health-related quality of life in gynecology and gynecologic oncology. This is despite 
complications being a central focus of surgical outcome measurement, and an increasing 
awareness of the need for patient-reported data when measuring surgical quality.
OBJECTIVE—We sought to measure the impact of surgical complications on health-related 
quality of life at 1 month postoperatively, in women undergoing gynecologic and gynecologic 
oncology procedures.
STUDY DESIGN—This is a prospective cohort study of women undergoing surgery by 
gynecologic oncologists at a tertiary care academic center from October 2013 through October 
2014. Patients were enrolled preoperatively and interviewed at baseline and 1, 3, and 6 months 
postoperatively. Health-related quality of life measures included validated general and disease-
specific instruments, measuring multiple aspects of health-related quality of life, including anxiety 
and depression. The medical record was abstracted for clinical data and surgical complications 
were graded using validated Clavien-Dindo criteria, and women grouped into those with and 
without postoperative complications. Bivariate statistics, analysis of covariance, responder 
analysis, and multivariate modeling was used to analyze the relationship of postoperative 
complications to change health-related quality of life from baseline to 1 month. Plots of mean 
scores and change over time were constructed.
RESULTS—Of 281 women enrolled, response rates were 80% (n = 231/281) at baseline, and 
from that cohort, 81% (n = 187/231), 74% (n = 170/231), and 75% (n = 174/231) at 1, 3, and 6 
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months, respectively. The primary analytic cohort comprised 185 women with completed baseline 
and 1-month interviews, and abstracted clinical data. Uterine (n = 84, 45%), ovarian (n = 23, 
12%), cervical (n = 17, 9%), vulvar (n = 3, 2%), and other (n = 4, 2%) cancers were represented, 
along with 53 (30%) cases of benign disease. There were 42 (24%) racial/ethnic minority women. 
Minimally invasive (n = 115, 63%) and laparotomy (n = 60, 32%) procedures were performed. 
Postoperative complications occurred in 47 (26%) of patients who experienced grade 1 (n = 12), 
grade 2 (n = 29), and grade 3 (n = 6) complications. At 1 month, physical (20.6 vs 22.5, P = .04) 
and functional (15.4 vs 18.3, P = .02) well-being, global physical health (43.1 vs 46.3, P = .02), 
and work ability (3 vs 7.2, P = .001)were lower in postoperative complication vs non-postoperative 
complication women. Relative change, however, in most health-related quality of life domains 
from baseline to 1 month did not differ between postoperative complication and nonpostoperative 
complication groups. Postoperative complication patients did have increased odds of sustained or 
worsened anxiety at 1 month vs baseline (odds ratio, 2.5; 95% confidence interval, 1.2–5.0) 
compared to nonpostoperative complication patients.
CONCLUSION—Collectively, women who experienced postoperative complications after 
gynecologic and gynecologic oncology procedures did not appear to have differences in most 
health-related quality of life trends over time compared to those who did not. An exception was 
anxiety, where postoperative complications were associated with sustained or worsened levels of 
high anxiety after surgery.
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Introduction
Patient-centered outcomes are of increasing importance in medical research. The Affordable 
Care Act1 provided $150 million in annual funding for the Patient-Centered Outcome 
Research Institute, an organization expressly committed to addressing the questions and 
concerns most relevant to patients when comparing treatment strategies.2 Although there is 
robust research on patient-centered outcomes among patients undergoing medical therapies, 
research in patient-centered outcomes after surgical procedures is lacking. In January 2015, 
funding from the Agency for Health Care Quality supported a stakeholder conference on 
patient-reported outcomes (PRO) in surgery with a major goal of prioritizing PRO research 
in surgery.3
An area of surgical quality that is under increasing scrutiny is surgical complications.4 
However, we are limited in our ability to measure them through our current surgical 
evaluation systems. The utility of complication data driven purely through administrative 
claims has been questioned.5 Claims data are a poor source of information regarding 
symptom burden and functional impairment, however these key aspects of health-related 
quality of life (HRQOL) can be reliably assessed via PRO measures.
Currently, the impact of surgical complications on patient-reported HRQOL is unknown. 
We,6 along with others7,8 have previously published on the relationship between 
preoperative HRQOL domains and postoperative complications. In this study we sought to 
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discover what aspects of HRQOL are affected by adverse surgical outcomes in a new, larger, 
prospective cohort. The goals of this study were to measure the impact of surgical 
complications on HRQOL in women undergoing gynecologic and gynecologic oncology 
procedures, using current commonly used PRO instruments to measure overall and cancer-
specific HRQOL. The primary outcome of change in HRQOL scores was measured at 1 
month, or 30 days, consistent with the commonly used 30-day window for postoperative 
complication assessment and postoperative recovery milestones.
Materials and Methods
Study design, enrollment, and data collection
We conducted a prospective longitudinal cohort study of women enrolled in the Health 
Registry/Cancer Survivorship Cohort (HR/CSC) at the University of North Carolina. This 
study was approved by the institutional review board (study no. 13-2367) and enrolled 
patients from October 2013 through October 2014, with final follow-up through May 2015. 
Under the HR/CSC protocol, patients were identified and recruited through the University of 
North Carolina health care oncology outpatient clinics with the following eligibility criteria: 
age ≥18 years; North Carolina mailing address; and English or Spanish speaking. Patients 
unable to provide informed consent or participate in interview questionnaires were excluded. 
For this study, eligibility was further restricted to HR/CSC patients recruited through the 
gynecologic oncology clinics, with newly diagnosed gynecologic cancer and planned 
surgical management. Initial exclusion criteria included primary surgery completed or to be 
completed at an outside institution, previous chemotherapy or radiation therapy, and 
pregnancy. After the first 10 weeks of enrollment, the exclusion criteria were modified to 
allow for retention of patients with final benign pathology to allow inclusion of women 
undergoing surgery for suspicious pelvic masses/suspected ovarian cancer. The exclusion 
criteria were also modified to include patients with prior, but not active, chemotherapy or 
radiation treatment to allow inclusion of patients with new recurrences.
Baseline interviews were conducted within 2 weeks of enrollment, prior to surgery, by 
trained staff using a computer-assisted telephone interview software tool specifically 
developed for the HR/CSC. Follow-up interviews were conducted at 1, 3, and 6 months after 
surgery. Patients were included who completed follow-up interviews within a 3-week 
interval around each targeted time point (1 week prior or up to 2 weeks after the target date 
[eg, 1, 3, or 6 months postsurgery]). Participants received gift cards as compensation after 
completion of each interview. Interview questionnaire topics included medical and social 
histories, and general and cancer-specific HRQOL assessments. The cohort was limited to 
participants who met all inclusion criteria and completed at least the baseline and 1-month 
interviews, as this was the primary outcome point of the analysis. As a secondary outcome, 
the 3- and 6-month data of this cohort were also reported.
The following validated questionnaires were included in this analysis: the Functional 
Assessment of Cancer Therapy (FACT)-General Population (GP),9 the PRO Measurement 
Information System (PROMIS) Global Health Short Form v1.0,10 PROMIS Anxiety 4-item 
Short Form11 and PROMIS Depression 4-item Short Form,11 and the modified Work Ability 
Index (WAI).12 The FACT-GP version 4 is a 21-item scale that measures 4 HRQOL 
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subscales: physical, functional, emotional, and social well-being. The minimally important 
difference (MID) for the FACT-GP is 5–7 points, and 2–3 points for each subscale. The 
FACT-GP covers a wide range of patient experiences (eg, pain, energy levels, social support) 
and is commonly used in gynecologic oncology clinical trials (Appendix). The PROMIS 
global is a 10-item scale including questions about fatigue, physical function, pain, 
emotional distress, and social health that are summarized into measures of physical and 
mental health. PROMIS scales are scored using T scores (0–100 scale), which are 
standardized to the US general population and have a mean of 50 and SD of 10. The 
modified WAI includes a subset of questions from the original scale, designed to assess 
work ability compared to lifetime best, in relation to mental and physical demands, and sick 
leave.12 The specific question analyzed for this study was, “Assume that your ability to work 
at its best has a value of 10 points and 0 means that you cannot currently work at all. How 
many points would you give your current ability to work?” with a 0–10 scale response.
Patients’ self-reported age, race/ethnicity, marital status, and employment status were 
obtained from the HR/CSC baseline interview. The electronic medical record was reviewed 
(physician, nursing, and case management staff documentation) to abstract clinical data at 
the time of new patient visit (body mass index [BMI], comorbid conditions, cancer site) and 
during the 30-day postoperative follow-up window (surgical procedure, postoperative 
complications, and adjuvant treatment plan). Composite variables of major medical 
comorbidity and postoperative complication were created as reported in previous studies.6,13 
The major comorbidity variable included notation in the record for at least 1 of these 
conditions: diabetes, pulmonary disease (chronic obstructive pulmonary disease, restrictive 
lung disease, home oxygen requirement), cardiac disease (congestive heart failure, history of 
myocardial infarction, coronary artery disease), immunocompromised states (HIV, chronic 
steroid use), and chronic kidney disease. Surgical complications were identified and graded 
using Clavien-Dindo criteria.14 All medical record abstraction data were limited to 
encounters at our institution, however patients were asked about outside medical encounters 
at each follow-up interview session. Those that reported encounters associated with surgical 
complications (n = 2) were recorded as experiencing a postoperative complication. Insurance 
status, at the time of the new patient visit, was also abstracted from the medical record. The 
medical record information was then merged with the HR/CSC demographic and interview 
data.
Statistical analysis
This study was designed to have 80% power to detect an effect size of 0.47 for comparing 
mean change in FACT-GP physical well-being scores between women with and without 
surgical complications at an alpha of 0.05. Change was defined for each woman as the 
difference in score between 1 month and baseline (ie, 1-month score – baseline score). We 
planned enrollment of 225 women, assuming 200 would have evaluable baseline and 1-
month data and 50 would have surgical complications. Based on our actual number of 
evaluable women of 187 (47 of whom had complications), we had 80% power to detect an 
effect size of 0.49.
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Summary statistics were generated using simple frequencies and percentages for categorical 
variables and mean with SD for continuous variables. Bivariate statistics using Student t 
tests for continuous data and χ2 tests for categorical data were used to compare baseline 
characteristics between women with and without complications. Histograms of survey scale 
responses were constructed to determine normality. The primary outcome, change in mean 
score from baseline to 1 month, was defined as Δ score = 1-month score – baseline score. 
Mean scores and mean change in scores of the FACT-GP and subscales, PROMIS global 
health, and PROMIS anxiety and depression scales were compared using Student t tests 
accounting for unequal variance. Multivariate linear regression models were constructed and 
adjusted for age, BMI, and any HRQOL scores that differed significantly at baseline. All 
other potential covariates were explored and were to be included only if they were associated 
(P < .05) with both the exposure (complications) and the outcomes (change in specific 
HRQOL score). No other covariates met these criteria.
To describe how HRQOL domains behaved within each group, we performed responder 
analyses by categorizing the trend in score change (from baseline to 1 month) into 3 groups: 
increased, no change, and decreased. This allowed us to examine what fraction of women in 
each group experienced improvement in a given HRQOL domain, compared to their 
baseline. Scores had to change in a magnitude greater than the MID for each scale to be 
categorized as increased or decreased. For example, the MID for the FACT-GP is 5–7. 
Therefore, only a score that increased by at least 5 points would be in that category. 
Otherwise, a score that changed by <5 points, in either direction, was grouped under “no 
change.” A Fisher exact test was used to compare proportions of each category between 
women with and without surgical complications. For the responder analysis that was 
statistically significant, the likelihood of increase/no change in score vs decrease was 
estimated using a multivariate logistic regression model. The question from the modified 
WAI was analyzed using parametric (Student t test) and nonparametric (Wilcoxon rank-sum 
test) approaches, given the 0–10 response scale and skewed sample sizes of the responders. 
For the secondary analysis, graphs of mean score over time, from baseline to 6 months, 
stratified by complication groups, were constructed.
Results
Study population
Of 281 women who consented for the study, 231 (82%) completed baseline interviews. Of 
the 50 nonparticipants, 12 were ineligible due to protocol or withdrawal, and 38 did not 
reply to interview requests. Of the 231 women who completed the baseline interview, 187 
completed 1-month interviews, 185 of whom had completed medical record abstraction data. 
These 185 comprised the final study cohort based on the a priori primary outcome measure. 
These 185 were 65% (185/281) of the initial enrollment cohort and 80% of those who 
completed baseline interviews. Subsequent follow-up rates, based on the baseline interview, 
were 74% (170/231) at 3 months and 75% (174/231) at 6 months for the secondary outcome 
measures (Figure 1).
From the 231 women who completed the baseline interview, responders and nonresponders 
at 1 month were assessed for differences in baseline characteristics. There was a greater 
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proportion of ovarian cancer in nonresponders (39% vs 12%), with associated greater 
proportion of debulking procedures (26% vs 10%), and composite postoperative 
complications (35% vs 25%). These differences were expected as ovarian cancer patients 
have the highest rate of complication and readmissions among gynecologic cancers, and thus 
may be the most difficult to follow up for serial interview assessments. Responders and 
nonresponders were balanced on all other characteristics (Supplemental Table 1).
Table 1 details the baseline characteristics of the main study cohort. Due to small numbers, 
non-white and non-black races were collapsed into an “other” category, which included 
Asian (n = 2, 1%), Native American (n = 3, 1.6%), and other (n = 5, 2.7%) respondents. 
There were 8 Hispanic women, 1 who identified as white, 1 as black, and 5 as other. There 
were 54 women with suspected malignancy who had benign disease on final pathology. 
These women were kept in the cohort, given they had procedures and therefore associated 
postoperative risks similar to those with cancer on final pathology. The group of women who 
experienced a postoperative complication had a larger proportion of ovarian cancer, 
unemployed status (including retired individuals), laparotomy, debulking surgery, bowel 
surgery, and adjuvant therapy compared to the women without complications.
There were 47 women with postoperative complications (Supplemental Table 2), of which 
12 were grade 1, 29 were grade 2, and 6 were grade 3. Baseline HRQOL scores were 
compared between women who did and did not have complications (Table 2). At baseline, 
the surgical complication group had a mean FACT physical well-being score 1.9 points 
lower (MID 2–3 points), and a PROMIS global physical health score 3.2 points lower (MID 
4–7 points) than the noncomplication group.
Surgical complications and HRQOL changes
The primary outcome was the effect of surgical complications on the degree of change in 
mean HRQOL scores from baseline to 1 month (Table 3). There were no statistically 
significant differences in the magnitude of change in scores between women with and 
without surgical complications on bivariate testing (not shown). The results of the 
multivariate linear regression are shown in Table 3. The models were adjusted for age, BMI, 
and the 2 baseline HRQOL scores that differed significantly between the groups: PROMIS 
physical health and the physical well-being subscale of the FACT-GP. The point estimates 
represent the adjusted difference in mean change (from baseline to 1 month), between those 
who did and did not have surgical complications. For example, for the functional well-being 
subscale, the mean change in score from baseline to 1-month postoperatively was 2.07 
points lower for the group that had complications, compared to the groups that did not (P = .
06). Although no results were statistically significant, the largest differences between the 
groups were in functional well-being, global physical health, and anxiety scores.
A trend was noted with the PROMIS anxiety measure, where women without surgical 
complications had an adjusted mean decrease in anxiety score double that of women with 
complications (6.1 vs 3.0 points, P = .07). A responder analysis was completed for each 
survey instrument, by grouping women into those whose scores increased, decreased, or had 
no change from baseline to 1 month. The proportions of the 3 groups were then compared 
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between those who did and did not have complications. These results were also 
nonsignificant (not shown), with the exception of the PROMIS anxiety measure.
Women with surgical complications were more likely to have increased or stable anxiety at 1 
month after surgery (66%, n = 31), compared to women who did not (44%, n = 61) (P = .03) 
(Supplemental Table 3). The 4 questions in PROMIS were: anxiety instrument focused on 
“feeling fearful,” “focusing on anxiety,” “feeling uneasy,” and feeling “worried or 
overwhelmed.” In the first 3 listed domains (fearful, focus on anxiety, unease), women who 
experienced a complication had higher mean scores (reflecting more of the feeling) than 
those who did not. The most notable difference was in the measure of feeling uneasy. In 
patients who experienced postoperative complications, 72% (n = 34/47) had feelings of 
unease that were no different or increased from their baseline, preoperative levels, compared 
to 50% (n = 69/138, P = .021). In a multivariate logistic regression model, adjusting for age, 
BMI, and baseline PROMIS physical health and physical well-being, patients who 
experienced a postoperative complication had an odds of stable or increased anxiety 2.6 
times that of patients who did not at 1 month after surgery (odds ratio, 2.63; 95% confidence 
interval, 1.25–5.6). Given that the entire cohort has baseline anxiety above the general 
population norms, this represents a clinically important effect of postoperative 
complications.
With regard to work ability, in the complication group, 22% (n = 4/18) of those working at 
baseline had returned to work at 1 month, compared to 66% (46/69) of those without 
complications. The WAI question was answered only by those currently working, limiting 
any further assessment due to small numbers of participants actively working at the 1-month 
time point.
Exploratory results by complication grade are also presented. Although very limited by a 
sample size of 6, among the grade 3 group, complications appear to have a greater impact on 
change in overall physical and mental HRQOL domains in multiple scales. This is shown 
graphically in Figure 2 where trends from baseline to 6 months post-operatively are shown. 
Figure 2, A, demonstrates the difference in score trend in FACT-GP among women without 
complications, those with grade 1–2 complications, and the severe grade 3 subgroup. It may 
be thought that the HRQOL trend in this small subgroup of severe complications simply 
reflects an increased likelihood of more complex surgery or chemotherapy toxicity. 
Therefore, for comparison sake, Figure 2, B, shows the FACT-GP trend among patients 
experiencing these other significant events of adjuvant chemotherapy and complex surgery, 
alongside the patients with severe complications.
Comment
In a cohort of women undergoing gynecologic and gynecologic oncology procedures, we 
found that the magnitude of change between preoperative and postoperative HRQOL did not 
differ significantly by the occurrence of surgical complications, with the exception of 
anxiety. Women who had surgical complications had greater odds of stable or increased 
anxiety at 1 month after surgery, compared to women who did not experience a 
complication. Absolute preoperative and postoperative scores on physical well-being and 
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functional well-being (as measured by the FACT-GP), global physical health (as measured 
by the PROMIS global health), and work ability (as measured by the WAI) are lower in 
women who experience post-operative complications, consistent with prior studies.6–8 This 
is among the few studies designed to prospectively test the impact of composite 
postoperative complications on HRQOL, and the first, to our knowledge, in gynecologic and 
gynecologic oncology patients.
Patient anxiety is not a benign condition. Anxiety in patients with cancer impacts levels of 
fatigue15 exacerbates chemotherapy-related nausea and vomiting,16 and is a predictor of 
dose delays and reductions.17 And, critically important within the postoperative, pre-
adjuvant treatment window, anxiety is related to less effective medical decision making.18,19 
Why some patients have more anxiety at baseline than others is poorly understood. Our 
results point to a possible mechanism, especially for cancer patients whose care often begins 
with surgery. It makes sense that an unexpected adverse event after surgery, no matter how 
minor, can contribute to feelings of unease and anxiety about health and further treatment. 
Surgical complications are often thought of as temporary events that are quickly resolved. If 
complications increase patient anxiety however, this suggests a mechanism for a longer term 
impact of even minor surgical complications than what is currently considered. It also 
reemphasizes the need for true baseline preoperative HRQOL measures in all oncology trials 
where surgery is a component of care. A systematic review of longitudinal anxiety in ovarian 
cancer patients, published in 20 1 5,20 featured 7 studies with labeled “pretreatment” 
baseline anxiety levels, only 1 of which actually reported preoperative baseline anxiety, and 
consisted of 27 patients total.21
Our secondary outcomes of HRQOL trends over 3 and 6 months did not have substantive 
differences between the complication and noncomplication groups, with the exception of the 
small subset of 6 patients with grade 3 complications. These are hypothesisgenerating data 
that support the role of a larger study that focuses on long-term HRQOL trends among 
women with grade ≥3 surgical complications.
Our study has important limitations to note. It is a single-institution study and therefore the 
results may not be generalizable in a broader population. We cannot comment on 
nonparticipation bias, as we do not have abstracted clinical information on the 38 women 
who were enrolled, remained eligible, but did not complete baseline and/or 1-month 
interviews. Although patients were asked at the 1-month interview about care received at 
outside institutions and possible complications, we may still be underestimating the 
complication rate due to lack of medical record data from other institutions. Unlike clinical 
trials, the proportion of black women (17%) in our study was representative of the larger 
state population (22%),22 however, we had under-representation of Hispanic women (3.4%) 
compared to the state (8%).22 This may in part be due to the relatively young median age of 
Hispanics in the state (33 years)23 compared to the median age of gynecologic oncology 
patients (49–68 years).24 We also had an overrepresentation of patients with private 
insurance (84%) compared to the state population of women age > 18 years (68%).22 This 
may be a population of higher socioeconomic status that in turn has greater ability to 
withstand the insult of postoperative complications, limiting the effect seen in our data. Our 
first postoperative assessment was at 1 month and each interview asked the patient to recall 
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experiences over the past 7 days. This schedule may have missed early 1–3 week 
experiences in surgical recovery, or in the intervening follow-up weeks, that may have 
resulted in changes in survey scores. Given the study design and power, we are unable to 
distinguish which kind of complications resulted in greater or lesser changes in HRQOL. In 
addition, we included multiple different procedure types that may inherently affect HRQOL 
differently, independent of complication. With regard to this, however, we used the same 
scales used in surgical randomized trials, where these scores were not found to differ by 
procedure type such as laparoscopy vs laparotomy or sphincter sparing surgery vs 
abdominoperineal repair.25,26 Finally, the results are not adjusted for multiple testing (9 
hypothesis tests) where more conservative P values could be employed. These results need 
replication in larger sample groups of cancer patients to assure sufficient statistical power for 
the anticipated effect size.
Our study has many unique aspects and strengths. We had a high response rate (>70%) at 
each assessment interval through the 6-month interviews, adding robustness to the follow-up 
data. The interviews were performed by independent trained administrators in person or over 
the telephone, limiting bias with literacy skills. Our assessments included standardized 
instruments to measure multiple aspects of HRQOL including depression and anxiety.
Our results have important implications for the selection of HRQOL measures in surgical 
trails. Although randomized controlled trials of surgery are rare, in essence they are 
performed to compare such outcomes as surgical complication and HRQOL between 2 
techniques. The FACT-GP is a commonly used HRQOL measure in gynecologic oncology 
trials. Yet, the ability of this tool to discriminate the impact of surgical complications on 
HRQOL was never tested. Although we cannot answer this definitely with our study design, 
our results suggest that the FACT-GP may have some reactivity to severe (grade ≥3) 
complications, but not the more minor complications. One may argue this level of sensitivity 
is reasonable, because minor complications are not important. However, in the current era of 
an emphasis on the patient experience, that may be a faulty assumption. Using a HRQOL 
instrument that fails to detect the impact of minor complications assumes these events are 
not important to a patient’s quality of life. The truth is that these events may matter greatly 
to some patients and not at all to others. We should have HRQOL measures designed for a 
surgical population, to allow patients to participate in shared decision making around 
surgery, with complete data.
PRO data are critically needed in surgical literature, especially in nonclinical trial 
populations and in patients with benign and malignant gynecologic disease, to facilitate 
decision making and treatment evaluation. Therefore, we need more survey measures that 
are specific to the surgical recovery experience for cancer patients, beyond the FACT-GP. We 
also need greater awareness and intervention methods for addressing the anxiety that may be 
a lasting effect of temporary surgical complications. The Society of Gynecologic Oncology, 
along with many others, is working to define the concepts of “value” and “quality” in 
surgical care. In addition to considering complication rates, we need to incorporate the 
impact of such complications, major and minor, on HRQOL.
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FIGURE 1. Study population
Response rate percentages represent respondents/eligible respondents, as detailed in right-
sided bubbles. After completion of baseline interview, participants could miss 1 of 3 follow-
up interviews and remain in study. For 1-month primary outcome, 2 patients were missing 
complete clinical records, yielding final primary cohort of N = 185. Participation rate at 1, 3, 
and 6 months is based on cohort that completed baseline interview (n = 231).
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FIGURE 2. Health-related quality of life score trends
Health-related quality of life score trends: from baseline to 6 months postoperatively. A, 
Mean scores of women with no complications (n = 137), grade 1 and 2 complications (n = 
41), and severe grade 3 complications (n = 6). B, Change in mean scores from baseline 
values, comparing those with severe grade 3 complications vs other postoperative groups 
without complications: women undergoing adjuvant chemotherapy (n = 51) and those who 
required complex surgery (n = 23).
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TABLE 1
Baseline characteristics of women undergoing gynecologic oncology surgery, overall and by occurrence of 
postoperative complicationa
Characteristics
Overall
N = 185 (100)
No postoperative complications
n = 137 (74)
Any postoperative complication
n = 47 (26)
Age, y, mean (SD) [range] 56.5 (13) [22–93] 56 (14) [22–93] 58 (12) [34–82]
Race
 White 143 (77) 107 (78)   36 (77)
 Black   32 (17)   24 (18)     8 (17)
 Other 10 (5)   7 (4)   3 (6)
Insurance
 None   14 (8)   11 (8)   3 (6)
 Medicare only     8 (4)     6 (4)   2 (4)
 Medicaid     7 (4)     6 (4)   1 (2)
 Any private   156 (84)   115 (83)   41 (87)
Marital status
 Partnered 114 (62)   84 (61)   30 (64)
 Single   51 (28)   40 (29)   11 (23)
 Widowed   20 (11)   14 (10)     6 (13)
Employment
 No   98 (53)   69 (50)   29 (62)
 Yes   87 (47)   69 (50)   18 (38)
Cancer site
 Uterine   84 (45)   63 (46)   21 (45)
 Ovary   23 (12) 13 (9)   10 (21)
 Cervix 17 (9)   14 (10)   3 (6)
 Vulva/vaginal     3 (1.6)      1 (0.7)   2 (4)
 Otherb  4 (2)      2 (1.4)   2 (4)
 Benign  54 (29)   45 (33)     9 (19)
Major comorbidityc
 No 163 (88) 124 (90)   39 (82)
 Yes   22 (12)   14 (10)     8 (17)
BMI, mean (SD) [range]                 32.9 (9) [17–58]                 32 (8.7) [17–56]                   34 (10.2) [19–58]
Procedure typed
 MISd 116 (63)   95 (69)   21 (45)
 Laparotomy   60 (32)   38 (28)   22 (47)
 Debulking   20 (10) 11 (8)     9 (19)
 Radical hysterectomy 13 (7) 10 (7)   3 (6)
 Bowel surgery 12 (7)   6 (4)     6 (13)
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Characteristics
Overall
N = 185 (100)
No postoperative complications
n = 137 (74)
Any postoperative complication
n = 47 (26)
Adjuvant therapye
 Yes   77 (42)   51 (37)   26 (55)
 No   55 (30)   43 (31)   12 (26)
 NAe   53 (29)   44 (32)     9 (19)
BMI, body mass index; MIS, minimally invasive surgery (including traditional and robotic-assisted laparoscopy); NA, not applicable (benign 
disease).
aAll data presented as no. (%) unless otherwise noted;
b
Includes: 1 patient with gynecologic malignancy, unknown primary, and 3 patients with final pathology of gastrointestinal origin;
c
Includes: diabetes, history of venous thromboembolism or stroke, chronic renal disease, immunosuppression, or cardiac disease (excluding 
hypertension);
d
These are nonexclusive categories of procedures performed and therefore do not add up to 100%;
e
Includes: chemotherapy, radiation, or hormonal therapy.
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TABLE 2
Baseline health-related quality-of-life scores by occurrence of surgical complications
Baseline
Surgical complication
Survey Mean (SD) No, n = 137 Yes, n = 47 P
FACT-GP 83.0 (18) 79.0 (22) .22
Physical 23.2 (4.8) 21.3 (7.0) .04
Functional 20.6 (6.7) 18.8 (6.2) .13
Emotional 16.4 (6.1) 16.0 (6.6) .71
Social 22.9 (5.2) 22.9 (6.4) .98
PROMIS global health
 Physical 47.8 (8.5) 44.6 (8.2) .03
 Mental 50.1 (7.9) 49.9 (9.3) .90
PROMIS anxiety 54.5 (8.7) 53.1 (9.5) .35
PROMIS depression 54.3 (6.6) 54.0 (6.5) .79
Currently working, n (%) 69 (50) 18 (39) .20
Work Ability Index   8.8 (2.3)
Median 10 [IQR 9–10]
  7.7 (3.2)
Median 9.5 [IQR 5–10] .13
a
FACT-GP, Functional Assessment of Cancer Therapy-General Population; IQR, interquartile range; PROMIS, Patient-Reported Outcomes 
Measurement Information System.
aWilcoxon rank-sum test.
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TABLE 3
Multivariate linear regression for change in health-related quality of life scores from baseline to 1 month after 
surgery, by occurrence of surgical complicationsa
Survey Point estimate 95% CI P value
Δ FACT-GP −1.89 −6.32 to 2.55 .40
 Δ Physical well-being −1.06 −2.65 to 0.52 .19
 Δ Functional well-being −2.07 −4.19 to 0.06 .06
 Δ Emotional well-being   0.08 −1.69 to 1.85 .93
 Δ Social well-being   0.44 −1.03 to 1.91 .55
PROMIS scales
Δ Global physical health −1.59 −3.81 to 0.62 .16
Δ Global mental health −1.92 −4.56 to 0.73 .15
Δ Anxiety   2.51 −0.47 to 5.49 .10
Δ Depression   0.48 −1.68 to 2.63 .66
CI, confidence interval; FACT-GP, Functional Assessment of Cancer Therapy-General Population; PROMIS, Patient-Reported Outcomes 
Measurement Information System.
a
Regression model for mean score change in complication group (vs no-complication group) adjusted for age, body mass index, baseline PROMIS 
physical health score, and baseline physical well-being subscale score. Point estimates are adjusted difference in mean change from baseline, 
between those who did and did not have surgical complications. Negative estimates indicate greater decrease in scores in complication group.
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